Phase 4 Vasculitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with aortitis (inflammation of the main artery from the heart) according to 2022 medical classification standards
- You are a woman or man between 18 and 65 years old
- Your disease is currently active, based on a specific scoring system called the NIH score (score of 2 or higher)
- If you are a woman who could become pregnant, you have tested negative for pregnancy and do not plan to become pregnant during the trial
- If you are currently taking a steroid medication (such as prednisone), your dose is not too high and has been stable for at least 4 weeks before joining
- If you are taking certain other medications for aortitis, you may need to stop taking them for a specific period of time before joining — the waiting period varies depending on which medication you take (confirm with trial site for details on your specific medication)
- If you have a positive TB screening test (T-SPOT) but no active tuberculosis, a specialist will review your case and preventive TB treatment may be needed before you can join
- If you have hepatitis B virus (HBV), your virus levels must be undetectable after 2–4 weeks of antiviral treatment before researchers decide if you can join
Who may not be able to join:
- You have a major organ that is failing
- You have had dialysis or a major surgical procedure within the past 3 months
- You have another autoimmune disease in addition to aortitis
- You have severe or rapidly worsening damage to an organ
- You have another health condition that is likely to require higher doses of steroid medication during the trial
- You have a history of cancer
- You have a serious active or long-term infection, including active tuberculosis or a positive hepatitis B surface antigen test
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lindi Jiang, PhD, Fudan University
Phone: +8618317070593
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effectiveness rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.